Edman S , McKay S , Macdonald LJ , Samadi M , Livesey MR , Hardingham GE , Wyllie DJ .

Biotechnology and Biological Sciences Research Council , Wellcome Trust , 088156 Wellcome Trust , G0902044 Medical Research Council , MRC_G0902044 Medical Research Council , WT088156 Wellcome Trust

	Fig. 1. TCN 201 antagonism of NMDAR-mediated responses is both subtype- and glycine-dependent and more potent than TCN 213. (ai), upper panel, molecular structure of TCN 201. Lower panel, TEVC currents recorded from an oocyte expressing GluN1/GluN2A NMDARs in response to application of glutamate (30 μM) and glycine (10 μM, left-hand trace; 30 μM, righthand trace). TCN 201 (10 μM) was applied as indicated and inhibited the glutamate/glycine-evoked response but the extent of the inhibition was dependent on the glycine concentration. (aii), upper panel, molecular structure of TCN 213. Lower panel, a series of similar TEVC current traces in equivalent conditions, but recorded in the presence of TCN 213 (10 μM). (aiii), bar graphs summarizing the mean data obtained from a series of experiments that investigated the glycine-dependency of TCN 201 (10 μM, n = 12; 30 μM, n = 8) and TCN 213 (10 μM, n = 11; 30 μM, n = 9) antagonism of steady-state responses at GluN1/GluN2A NMDARs. (b), a series of representative TEVC current traces illustrating similar experiments as in (a), but where the glycine concentration was fixed (30 μM) and glutamate was applied at either 3, 10 or 30 μM. The bar graph summarizes the mean data obtained from a series of experiments that investigated the glutamate-dependency of TCN 201 antagonism of steady-state responses at GluN1/GluN2A and NMDARs at 3 μM (n = 5), 10 μM (n = 6) and 30 μM (n = 6). (c), a series of representative TEVC current traces illustrating similar experiments to that shown in (a), but for recordings made from oocytes expressing GluN1/GluN2B NMDARs. Note here the modest inhibition produced by TCN 201. The bar graph summarizes the mean data obtained from a series of experiments that investigated the glycine-dependency of TCN 201 antagonism of steady-state responses at GluN1/GluN2B NMDARs at 3 μM (n = 6), 10 μM (n = 6) and 30 μM (n = 6).
	Fig. 2. Inhibition curves for TCN 201 antagonism of GluN1/GluN2A NMDAR-mediated responses activated by co-agonists glycine or d-serine. (ai), TEVC trace recorded from an oocyte expressing GluN1/GluN2A NMDARs and voltage-clamped at −30 mV. The upper bar in this trace and in panels (aii), (ci) and (cii) indicates the duration of the bath application of glutamate/glycine, while the shaded bar in this panel (and in (ai), (ci) and (cii)) indicates the co-application TCN 201. Increasing concentrations of TCN 201 were applied, cumulatively, as indicated by the arrowheads. (aii), as in (ai), but currents are evoked using a higher concentration of glycine (30 μM). Note that TCN 201-mediated inhibition is less at this higher glycine concentration. (b), mean normalised inhibition curves for TCN 201 block of GluN1/GluN2A NMDAR-mediated currents evoked by glutamate (30 μM) and either 3 μM (n = 15; ■), 10 μM (n = 5; ) or 30 μM (n = 10; ) glycine. The solid curves show the fit with the minimum fitted as a free parameter, whereas the dashed curves show the fit of the data points when the minimum valued was constrained to 0 (see Materials and methods). (ci), as in (ai) but where currents were evoked by glutamate (30 μM) and d-serine (3 μM), again increasing concentrations of TCN 201 (0.03–10 μM) were applied, cumulatively, as indicated by the arrowheads. (cii), as in (ci), but where currents were the d-serine was 30 μM. (d), mean normalised inhibition curves for TCN 201 block of GluN1/GluN2A NMDAR-mediated currents activated by glutamate (30 μM) and either 3 μM (n = 6; ■), 10 μM (n = 6; ) or 30 μM (n = 6; ) d-serine.
	Fig. 3. Schild analysis of TCN 201 antagonism of GluN1/GluN2A NMDAR-mediated responses. (a), illustration of a set of TEVC current traces, obtained from an oocyte expressing GluN1/GluN2A NMDARs, used to generate ‘two-point’ dose–response curves in either the absence or presence of TCN 201 (0.3 and 1 μM; n = 7). (b), as in (a) but for higher TCN 201 concentrations (3 and 10 μM; n = 7). (c) and (d), partial, low-concentration, dose–response curves obtained from the TEVC current traces illustrated in (a) and (b), respectively, and used to estimate dose ratios (DR0.3, 1, 3, 10). The slope of the fitted line to the control responses (no TCN 201; ■) was used to fit the responses obtained in the presence of 0.3 μM (), 1 μM (), 3 μM () and 10 μM (). (e), Schild plot for antagonism by TCN 201 of GluN1/GluN2A NMDARs using dose-ratios estimated from a series experiments such as that illustrated in (c) and (d). A ‘free’ fit of the 0.3, 1 and 3 μM TCN 201 data points gave has a slope of 0.98 which was considered not to be significantly different from 1 (95% confidence interval: 0.85–1.14). Thus the solid line is the fit of the respective data points to the Schild equation (i.e. the slope of this line is unity). The intercept on the abscissa (where the log10 value of the dose-ratio – 1 equals zero) gives an equilibrium constant (KB) value for TCN 201 of 70 nM. Data from McKay et al. (2012) where the KB value for TCN 213 was determined, is illustrated in grey for reference. The dotted line shows the fit of all data points with a modified equation (see Material and methods; Christopoulos and Kenakin, 2002) that takes into account allosteric modulation of glycine binding by TCN 201. The fit predicts an allosteric KB# value of 56 nM and an allosteric constant (α) of 0.0123. (f), Schild plot for antagonism by TCN 201 of GluN1/GluN2A NMDARs but using d-serine, rather than glycine, as the GluN1-site agonist. Again the solid line is the fit of the data to the Schild equation and gives a KB value for TCN 201 in these experiments of 81 nM. The dotted line shows the fit of all data points to the modified equation and predicts an allosteric KB# value of 66 nM and an allosteric constant of 0.0106.
	Fig. 4. Antagonism by TCN 201 of native NMDAR-mediated responses in rat cortical cultures. (a), left, example steady-state whole-cell currents activated by NMDA (50 μM) and glycine (3 μM) recorded from cortical pyramidal cells voltage-clamped at −70 mV from (ai), DIV 9–10 neurones, (aii), DIV 9–10 neurones transfected with GluN2A NMDAR subunits, and (aiii), DIV 15–18 neurones. To the right, traces illustrate the sensitivity of each of these NMDAR-mediated currents to the GluN2B-selective antagonist, ifenprodil (3 μM) and the subsequent sensitivity of the ifenprodil-insensitive component of this current to TCN 201 (10 μM). (b), left, bar graph summarizing the mean percentage ifenprodil block of NMDAR-mediated currents recorded from DIV 9–10 neurones (n = 7), GluN2A-transfected DIV 9–10 neurones (n = 6), and DIV 15–18 neurones (n = 9). Right, mean percentage TCN 201 block (expressed as a percentage of the original current magnitude) of NMDAR-mediated currents recorded from neurones in each of the three categories illustrated in (a). (c), plot illustrating the extent of ifenprodil and TCN 201 antagonism of NMDA-evoked currents from the same cell. Despite a wide range in the amount of block produced by either ifenprodil or TCN 201 (particularly for recordings from GluN2A-transfected and from neurones in older cultures) the data show a strong (negative) correlation (R2 = 0.91).

Alexander, Guide to Receptors and Channels (GRAC), 5th edition. 2011, Pubmed

Alexander, Guide to Receptors and Channels (GRAC), 5th edition. 2011, Pubmed
ARUNLAKSHANA, Some quantitative uses of drug antagonists. 1959, Pubmed
Auberson, 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. 2002, Pubmed
Bading, Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. 1991, Pubmed
Bettini, Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. 2010, Pubmed
Carmignoto, Activity-dependent decrease in NMDA receptor responses during development of the visual cortex. 1992, Pubmed
Chazot, Biochemical evidence for the existence of a pool of unassembled C2 exon-containing NR1 subunits of the mammalian forebrain NMDA receptor. 1997, Pubmed
Chen, Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. 2006, Pubmed
Chen, Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. 2008, Pubmed , Xenbase
Chen, Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. 2005, Pubmed , Xenbase
Christopoulos, G protein-coupled receptor allosterism and complexing. 2002, Pubmed
Collingridge, A nomenclature for ligand-gated ion channels. 2009, Pubmed
Crair, A critical period for long-term potentiation at thalamocortical synapses. 1995, Pubmed
Erreger, Glutamate receptor gating. 2004, Pubmed
Erreger, Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. 2007, Pubmed , Xenbase
Fischer, Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. 1997, Pubmed , Xenbase
Flint, NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. 1997, Pubmed
Frizelle, Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. 2006, Pubmed , Xenbase
Hansen, Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. 2012, Pubmed
Hestrin, Developmental regulation of NMDA receptor-mediated synaptic currents at a central synapse. 1992, Pubmed
Johnson, Glycine potentiates the NMDA response in cultured mouse brain neurons. , Pubmed
Kleckner, Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. 1988, Pubmed , Xenbase
Martel, In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. 2009, Pubmed
Martel, The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. 2012, Pubmed
McKay, Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. 2012, Pubmed , Xenbase
Monyer, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. 1994, Pubmed
Monyer, Heteromeric NMDA receptors: molecular and functional distinction of subtypes. 1992, Pubmed
Mott, Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. 1998, Pubmed , Xenbase
Neyton, Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. 2006, Pubmed
Ogden, New advances in NMDA receptor pharmacology. 2011, Pubmed
Otton, Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. 2011, Pubmed , Xenbase
Papadia, Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. 2008, Pubmed
Rauner, Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. 2011, Pubmed
Rutter, Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. 2000, Pubmed
Schorge, Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. 2003, Pubmed
Sheng, Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. 1994, Pubmed
Soriano, Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. 2008, Pubmed
Stocca, Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. 1998, Pubmed
Sugihara, Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. 1992, Pubmed , Xenbase
Traynelis, Glutamate receptor ion channels: structure, regulation, and function. 2010, Pubmed
Williams, Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. 1993, Pubmed , Xenbase
Wrighton, Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. 2008, Pubmed , Xenbase
Wyllie, Taking the time to study competitive antagonism. 2007, Pubmed